Article: Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleEffect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial
AuthorsLai, KC1
Lau, CS1
Ip, WY1
Wong, BCY1
Hui, WM1
Hu, WHC1
Wong, RWM1
Lam, SK1
Issue Date2003
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
CitationAlimentary Pharmacology And Therapeutics, 2003, v. 17 n. 6, p. 799-805 [How to Cite?]
DOI: http://dx.doi.org/10.1046/j.1365-2036.2003.01528.x
AbstractBackground: There is controversy as to whether Helicobacter pylori and non-steroidal anti-inflammatory drugs interact to cause peptic ulcers. Aim: To study whether the eradication of H. pylori in patients on long-term non-steroidal anti-inflammatory drug therapy prevents the development of ulcers. Methods: Patients infected with H. pylori whilst receiving long-term non-steroidal anti-inflammatory drug therapy, but with no ulcers at baseline endoscopy, were randomized to receive either triple antibiotic therapy (metronidazole 300 mg, clarithromycin 250 mg and amoxicillin 500 mg, given four times daily: n = 70) or placebo (n = 70) for 2 weeks. Non-steroidal anti-inflammatory drugs were continued throughout the study period. Endoscopy was repeated 12 weeks after the end of treatment. The development of ulcers was compared between the two groups. Results: Endoscopy at 12 weeks revealed peptic ulcer development in five [7%; 95% confidence interval (CI), 2-16] of the patients who received triple therapy and in six (9%; 95% CI, 3-18) of those who received placebo (P = 1.00). No significant difference in the development of ulcers was found between patients with persistent H. pylori infection (7/80; 9%; 95% CI, 4-17) and those with the eradication of H. pylori (4/52; 8%; 95% CI, 2-19) (P = 1.00). Conclusions: The eradication of H. pylori in patients receiving long-term treatment with non-steroidal anti-inflammatory drugs did not prevent ulcer development. However, because the rate of ulcer development was low, a study with a larger sample size is required to confirm this finding.
ISSN0269-2813
2011 Impact Factor: 3.769
2011 SCImago Journal Rankings: 0.338
DOIhttp://dx.doi.org/10.1046/j.1365-2036.2003.01528.x
ISI Accession Number IDWOS:000181634100007
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorLai, KC
dc.contributor.authorLau, CS
dc.contributor.authorIp, WY
dc.contributor.authorWong, BCY
dc.contributor.authorHui, WM
dc.contributor.authorHu, WHC
dc.contributor.authorWong, RWM
dc.contributor.authorLam, SK
dc.date.accessioned2010-09-17T10:21:44Z
dc.date.available2010-09-17T10:21:44Z
dc.date.issued2003
dc.description.abstractBackground: There is controversy as to whether Helicobacter pylori and non-steroidal anti-inflammatory drugs interact to cause peptic ulcers. Aim: To study whether the eradication of H. pylori in patients on long-term non-steroidal anti-inflammatory drug therapy prevents the development of ulcers. Methods: Patients infected with H. pylori whilst receiving long-term non-steroidal anti-inflammatory drug therapy, but with no ulcers at baseline endoscopy, were randomized to receive either triple antibiotic therapy (metronidazole 300 mg, clarithromycin 250 mg and amoxicillin 500 mg, given four times daily: n = 70) or placebo (n = 70) for 2 weeks. Non-steroidal anti-inflammatory drugs were continued throughout the study period. Endoscopy was repeated 12 weeks after the end of treatment. The development of ulcers was compared between the two groups. Results: Endoscopy at 12 weeks revealed peptic ulcer development in five [7%; 95% confidence interval (CI), 2-16] of the patients who received triple therapy and in six (9%; 95% CI, 3-18) of those who received placebo (P = 1.00). No significant difference in the development of ulcers was found between patients with persistent H. pylori infection (7/80; 9%; 95% CI, 4-17) and those with the eradication of H. pylori (4/52; 8%; 95% CI, 2-19) (P = 1.00). Conclusions: The eradication of H. pylori in patients receiving long-term treatment with non-steroidal anti-inflammatory drugs did not prevent ulcer development. However, because the rate of ulcer development was low, a study with a larger sample size is required to confirm this finding.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2003, v. 17 n. 6, p. 799-805 [How to Cite?]
DOI: http://dx.doi.org/10.1046/j.1365-2036.2003.01528.x
dc.identifier.doihttp://dx.doi.org/10.1046/j.1365-2036.2003.01528.x
dc.identifier.epage805
dc.identifier.hkuros81290
dc.identifier.isiWOS:000181634100007
dc.identifier.issn0269-2813
2011 Impact Factor: 3.769
2011 SCImago Journal Rankings: 0.338
dc.identifier.issue6
dc.identifier.pmid12641502
dc.identifier.scopuseid_2-s2.0-0037444981
dc.identifier.spage799
dc.identifier.urihttp://hdl.handle.net/10722/91583
dc.identifier.volume17
dc.languageeng
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
dc.publisher.placeUnited Kingdom
dc.relation.ispartofAlimentary Pharmacology and Therapeutics
dc.relation.referencesReferences in Scopus
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAmoxicillin - therapeutic use
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal - therapeutic use
dc.subject.meshClarithromycin - therapeutic use
dc.subject.meshDouble-Blind Method
dc.subject.meshDrug Therapy, Combination - therapeutic use
dc.subject.meshDuodenal Ulcer - prevention & control
dc.subject.meshDyspepsia - etiology
dc.subject.meshEndoscopy, Gastrointestinal
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHelicobacter Infections - drug therapy
dc.subject.meshHelicobacter pylori
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMetronidazole - therapeutic use
dc.subject.meshMiddle Aged
dc.subject.meshStomach Ulcer - prevention & control
dc.titleEffect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong